Compound Reviews
Cagrilintide: A Long-Acting Amylin Analogue
Amylin is co-secreted with insulin and signals satiety through the brainstem. Cagrilintide is the engineered, long-duration version studied alongside incretin compounds.
July 24, 2026 · 6 min read · Novanta Research
The native hormone problem
Human amylin aggregates readily into amyloid fibrils, which makes the native sequence unsuitable as a stable therapeutic or research molecule. Every practical amylin analogue is a redesign around that aggregation problem.
Cagrilintide addresses it with substitutions that suppress fibril formation, combined with a lipid side chain that binds albumin and extends duration substantially.
Receptor pharmacology
Amylin receptors are formed when the calcitonin receptor associates with receptor activity-modifying proteins. Published characterisation of cagrilintide describes activity across amylin receptor subtypes and at the calcitonin receptor itself, which is why it is sometimes described as a dual amylin and calcitonin receptor agonist.
Signalling from these receptors in brainstem regions is the described basis for satiety effects reported in animal work.
Why it appears alongside GLP-1 compounds
Amylin and incretin pathways are distinct, so combining them is mechanistically non-redundant. That is the rationale behind the combination studies in the published literature rather than any claim that one replaces the other.
Keep reading
For laboratory and research use only. Not for human or veterinary consumption. Novanta Research is not a compounding pharmacy and nothing in this article is medical advice or a claim that any compound diagnoses, treats, cures or prevents any condition.